Fintel reports that on November 18, 2024, Stephens & Co. initiated coverage of Catalyst Pharmaceuticals (NasdaqCM:CPRX) with a Overweight recommendation.
Analyst Price Forecast Suggests 48.37% Upside
As of October 22, 2024, the average one-year price target for Catalyst Pharmaceuticals is $30.89/share. The forecasts range from a low of $27.27 to a high of $39.90. The average price target represents an increase of 48.37% from its latest reported closing price of $20.82 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Catalyst Pharmaceuticals is 267MM, a decrease of 42.05%. The projected annual non-GAAP EPS is 0.97.
What is the Fund Sentiment?
There are 636 funds or institutions reporting positions in Catalyst Pharmaceuticals. This is an increase of 63 owner(s) or 10.99% in the last quarter. Average portfolio weight of all funds dedicated to CPRX is 0.20%, an increase of 3.37%. Total shares owned by institutions increased in the last three months by 12.45% to 120,928K shares. 
The put/call ratio of CPRX is 0.12, indicating a bullish outlook.
What are Other Shareholders Doing?
BlackRock holds 19,017K shares representing 15.94% ownership of the company.
IJR - iShares Core S&P Small-Cap ETF holds 7,256K shares representing 6.08% ownership of the company. In its prior filing, the firm reported owning 7,554K shares , representing a decrease of 4.11%. The firm decreased its portfolio allocation in CPRX by 3.06% over the last quarter.
Deerfield Management Company, L.p. holds 6,230K shares representing 5.22% ownership of the company. In its prior filing, the firm reported owning 9,127K shares , representing a decrease of 46.51%. The firm decreased its portfolio allocation in CPRX by 21.33% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,549K shares representing 2.98% ownership of the company. In its prior filing, the firm reported owning 3,487K shares , representing an increase of 1.76%. The firm decreased its portfolio allocation in CPRX by 3.81% over the last quarter.
CALF - Pacer US Small Cap Cash Cows 100 ETF holds 2,936K shares representing 2.46% ownership of the company. In its prior filing, the firm reported owning 529K shares , representing an increase of 81.99%. The firm increased its portfolio allocation in CPRX by 22.17% over the last quarter.
Catalyst Pharmaceuticals Background Information
(This description is provided by the company.)
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and other neurological and neuromuscular disorders. Catalyst's New Drug Application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration ('FDA'), and Firdapse is now commercially available in the United States. Further, Canada's national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
